Join
Live feed
·
PRReleasevia Quantisnow
Pardes Biosciences Inc. logo

Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022

ByQuantisnow·Wall Street's wire, on your screen.
PRDS· Pardes Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRDS (Pardes Biosciences Inc.) and more on Quantisnow.